(NASDAQ: MNKD) Mannkind's forecast annual revenue growth rate of 10.83% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.89%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.84%.
Mannkind's revenue in 2025 is $301,736,000.On average, 3 Wall Street analysts forecast MNKD's revenue for 2025 to be $97,505,749,266, with the lowest MNKD revenue forecast at $96,313,414,357, and the highest MNKD revenue forecast at $99,154,644,739. On average, 3 Wall Street analysts forecast MNKD's revenue for 2026 to be $109,738,074,498, with the lowest MNKD revenue forecast at $101,345,399,051, and the highest MNKD revenue forecast at $114,649,475,656.
In 2027, MNKD is forecast to generate $127,235,573,958 in revenue, with the lowest revenue forecast at $126,216,903,886 and the highest revenue forecast at $128,254,244,030.